首页> 美国卫生研究院文献>Molecular Therapy. Methods Clinical Development >Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing
【2h】

Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing

机译:整合酶缺陷型慢病毒载体作为高效CRISPR / Cas9介导的基因编辑的多平台平台

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The CRISPR/Cas9 systems have revolutionized the field of genome editing by providing unprecedented control over gene sequences and gene expression in many species, including humans. Lentiviral vectors (LVs) are one of the primary delivery platforms for the CRISPR/Cas9 system due to their ability to accommodate large DNA payloads and sustain robust expression in a wide range of dividing and non-dividing cells. However, long-term expression of LV-delivered Cas9/guide RNA may lead to undesirable off-target effects characterized by non-specific RNA-DNA interactions and off-target DNA cleavages. Integrase-deficient lentiviral vectors (IDLVs) present an attractive means for delivery of CRISPR/Cas9 components because: (1) they are capable of transducing a broad range of cells and tissues, (2) have superior packaging capacity compared to other vectors (e.g., adeno-associated viral vectors), and (3) they are expressed transiently and demonstrate very weak integration capability. In this manuscript, we aimed to establish IDLVs as a means for safe and efficient delivery of CRISPR/Cas9. To this end, we developed an all-in-one vector cassette with increased production efficacy and demonstrated that CRISPR/Cas9 delivered by the improved IDLV vectors can mediate rapid and robust gene editing in human embryonic kidney (HEK293T) cells and post-mitotic brain neurons in vivo, via transient expression and with higher gene-targeting specificity than the corresponding integrase-competent vectors.
机译:CRISPR / Cas9系统通过提供对包括人类在内的许多物种的基因序列和基因表达的空前控制,彻底改变了基因组编辑领域。慢病毒载体(LVs)是CRISPR / Cas9系统的主要传递平台之一,因为它们能够容纳较大的DNA负载并在广泛的分裂和非分裂细胞中维持稳定的表达。但是,LV传递的Cas9 /向导RNA的长期表达可能会导致不良的脱靶效应,其特征是非特异性RNA-DNA相互作用和脱靶DNA裂解。缺乏整合酶的慢病毒载体(IDLV)提供了一种诱人的CRISPR / Cas9组件递送方式,因为:(1)它们能够转导广泛的细胞和组织,(2)与其他载体相比具有卓越的包装能力(例如,腺相关病毒载体)和(3)瞬时表达并显示出非常弱的整合能力。在本手稿中,我们旨在建立IDLV作为安全有效地递送CRISPR / Cas9的手段。为此,我们开发了一种具有提高生产效率的多合一载体盒,并证明了由改进的IDLV载体传递的CRISPR / Cas9可以介导人类胚胎肾脏(HEK293T)细胞和有丝分裂后脑中的快速而强大的基因编辑通过瞬时表达并具有比相应整合酶支持载体更高的基因靶向特异性,通过活体神经元

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号